RESEARCH PAPER
TREATMENT RESISTANT HEPATIC ENCEPHALOPATHY IN THE COURSE OF ALCOHOLIC CIRRHOSIS
			
	
 
More details
Hide details
	
	
									
				1
				Studenckiego Koła Naukowego przy Katedrze i Klinice Chorób Wewnętrznych  Uniwersytetu Medycznego w Lublinie
				 
			 
						
				2
				Z Katedry i Kliniki Chorób Wewnętrznych Uniwersytetu Medycznego w Lublinie
				 
			 
						
				3
				Studenckiego Koła Naukowego przy Katedrze i Klinice Chorób Wewnętrznych Uniwersytetu Medycznego w Lublinie
				 
			 
										
				
				
		
		 
			
			
		
		
		
		
		
		
	
							
																								
		
	 
		
 
 
Med Og. 2009;15(3):431-442
 
 
KEYWORDS
ABSTRACT
Hepatic coma is a complex of disorders of the central nervous system that occur in the course of acute or chronic liver diseases. Alcohol abuse is the main factor leading to hepatic cirrhosis in adults.  Alcohol  is  the  cause  of  50%  of  all  cases  of  hepatic  cirrhosis  in  Western  countries, and probably  also  in  Poland.  Women  are  more  susceptible  to  liver  damage  due  to  alcohol; the permissible dose is several times lower, while the progress of the disease is more rapid. 
The case of a 43-year-old female patient is presented, admitted to the Clinic as an emergency case due to symptoms of  hepatic coma in the course of toxic alcoholic cirrhosis. 
The patient had been abusing high proof alcohol since the age of 20. 
During  hospitalization  of  the  patient,  the  increasing  ascites  and  secondary  anemia  were observed. According to the West Haven Criteria, grade IV b hepatic coma was defined, whereas by means of the Child- Pugh scale hepatic failure was classified into class C. 
Ultrasonography confirmed the features of hepatic cirrhosis. 
In laboratory tests, features of the damage of the liver parenchyma were observed: ALAT 622 IU/l, ASPAT 4052 IU/l, total bilirubin 14,75 mg/dl. Examinations of the coagulation system demonstrated:  INR  presenting  the  value  of  2.74,  prothrombin  time  between  30.4  and  31.6  s, APTT from 53.90 to 67.20 s. 
The  treatment  covered  application  of  the  following:  Lactulosum,  Neomycinum,    Ornithini aspartas,  Phytomenadionum,  Spironolactonum,  Furosemidum.  The  patient  was  transfused 2 doses of erythrocyte mass. 
After the application of treatment, a transitory improvement of the patient’s general health status  was  obtained.  Subsequently,  paracentesis  was  performed  due  to  the  proceeding  ascites, resulting in the letting of 5 litres of liquids. Bacteriological inoculation identified E.coli.  
On the 15th day the patient died due to the massive bleeding from the alimentary tract, as well as other body foramen.
		
	
		
REFERENCES (19)
			
	1.
	
		Blei A.T., Cordoba J.: Hepatic encephalopathy. The American Journal of Gastroenerology 2001, 96, 1968 - 1976.
		
	 
	 
 			
	2.
	
		Butterworth RF. Hepatic encephalopathy. Neurologist 1995, 1, 95 - 104.
		
	 
	 
 			
	3.
	
		de Bruijn K.M., Blendis L.M., Zilm D.H., Carlen P.L., Anderson G.H. Effect of dietary protein manipulations in subclinical portal- systemic encephalopathy. Gut 1983, 24, 53 - 60.
		
	 
	 
 			
	4.
	
		Gładysz A.: Leczenie ostrej encefalopatii wątrobowej. Leczenie chorób wątroby. Volumed, Wrocław 1996.
		
	 
	 
 			
	5.
	
		Gonciarz Z., Mazur W.: Alkoholowa choroba wątroby. W: Gastroenterologia i hepatologia kliniczna. Red. Konturek S.J. WL PZWL, Warszawa 2001, 598 - 603.
		
	 
	 
 			
	6.
	
		Gutkowski K., Gutkowska D.: Encefalopatia wątrobowa - aktualne metody leczenia. Gastroenterologia Polska 2005, 12, 6, 517 - 523.
		
	 
	 
 			
	7.
	
		Hartleb M., Czech E.: Alkoholowa choroba wątroby. Przegląd Gastroenterologiczny 2007, 2, 2, 92 - 100.
		
	 
	 
 			
	8.
	
		Helewski K.J., Kowalczyk-Ziomek G.I., Konecki J.J.: Postępowanie terapeutyczne w encefalopatii wątrobowej. Wiad. Lek. 2002, 55, 5/6, 301 - 309.
		
	 
	 
 			
	9.
	
		Juszczyk J.: Marskość wątroby, 2001, 3, 27, 12 - 17.
		
	 
	 
 			
	10.
	
		Juszczyk J.: Wiadomości hepatologiczne. Wątroba alkohol. Pol. Tyg. Lek., 1983, 50, 1588 - 1590.
		
	 
	 
 			
	11.
	
		Karsan H.A., Rojter S.E., Saab S.: Primary prevention of cirrhosis. Med., 2004, 115, 1, 25 - 30.
		
	 
	 
 			
	12.
	
		Krawczyk M.: Wodobrzusze oporna na leczenie. Medycyna Praktyczna - Chirurgia 2000, 4/5.
		
	 
	 
 			
	13.
	
		Mach T.: Encefalopatia wątrobowa - patogeneza, rozpoznanie i leczenie. Nowa Klinika 2003, 10, 1/2, 81 - 86.
		
	 
	 
 			
	14.
	
		Plauth M., Merli M., Kondrup J.: ESPEN Guidelines for nutrion in liver disease and transplantation. Clin. Nutr. 1997, 16, 43 - 47.
		
	 
	 
 			
	15.
	
		Schabowski J.: Alkoholowa choroba wątroby. Medycyna Ogólna 2003, 9, 4, 309 - 318.
		
	 
	 
 			
	16.
	
		Schabowski J., Saran T., Skrzydło-Radomańska B., Danilkiewicz W.C.: Magnesium extretion is reduced in patients with hepatocellulare carcinoma, chronic hepatitis and hepatic cirhosis. Experimental and Clinical Physiology and Biochemistry 2001, 1, 13, 94 - 96.
		
	 
	 
 			
	17.
	
		Schabowski J., Skrzydło-Radomańska B., Danilkiewicz C.: Level of zinc and coper in blond serum and urine of patients with hepatocellular carcinoma and hepatic cirrhosis. XI International Congress of Liver Diseases. Liver Cirhosis and its development. Abstracts Part II of the Basel Liver Week 1999, 352.
		
	 
	 
 			
	18.
	
		Sherloc S., Dooley J.: Diseases of the liver and biliary system. Blackwell Publishing, Paris 2002, 368.
		
	 
	 
 			
	19.
	
		Szczeklik A. i wsp.: Choroby wewnętrzne 2005, 942 - 948.